Scholarlink

Background <p>Previous evidence suggests a potential protective effect of warfarin against cancer, compared to non-users. However, it may be prone to immortal time bias and residual confounding.</p> Objective <p>We aimed to examine the association between cancer and warfarin, compared with active comparator (direct oral anticoagulants).</p> Methods <p>We conducted studies using population-based databases from England and Hong Kong to investigate the association between warfarin and hazard of cancer using a new-user active-comparator cohort design. People with atrial fibrillation aged ≥&#xa0;18&#xa0;years who had first received anticoagulant treatment during 01/01/2011–31/12/2019 were involved.</p> Results <p>No evidence supported the association between warfarin and hazard of overall cancer, compared with direct oral anticoagulants in both settings (England: hazard ratio [HR]&#xa0;=&#xa0;1.03, 95% confidence interval [CI] 0.94–1.13; Hong Kong: HR&#xa0;=&#xa0;0.89, 95% CI 0.79–1.01). A lower hazard of female breast (HR&#xa0;=&#xa0;0.49, 95% CI 0.30–0.79), ovarian (HR&#xa0;=&#xa0;0.07, 95% CI 0.01–0.58), and pancreatic (HR&#xa0;=&#xa0;0.46, 95% CI 0.22–0.96) cancers and a higher hazard of kidney cancer (HR&#xa0;=&#xa0;3.57, 95% CI 1.64–7.76) were found in Hong Kong, comparing warfarin with direct oral anticoagulants, but these were not replicated in England.</p> Conclusions <p>This study does not find a protective effect of warfarin against cancer versus direct oral anticoagulants. The risks of site-specific cancers including pancreatic, kidney, and sex-specific cancers between oral anticoagulants shown in the Hong Kong setting only may require further investigation in other independent datasets.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Risk of Cancer Comparing Warfarin and Direct Oral Anticoagulants: Population-Based Cohort Studies in England and Hong Kong

  • 期刊论文

  • 发表日期：

    2026年1月19日

查看全文
  • Zixuan Wang,
  • Qiuyan Yu,
  • Julian Matthewman,
  • John Tazare,
  • Sara Benitez Majano,
  • Jeremy Brown,
  • Ka Shing Cheung,
  • Celine S. L. Chui,
  • Esther W. Y. Chan,
  • Krishnan Bhaskaran,
  • Ian C. K. Wong,
  • Ian J. Douglas,
  • Angel Y. S. Wong

摘要

Background

Previous evidence suggests a potential protective effect of warfarin against cancer, compared to non-users. However, it may be prone to immortal time bias and residual confounding.

Objective

We aimed to examine the association between cancer and warfarin, compared with active comparator (direct oral anticoagulants).

Methods

We conducted studies using population-based databases from England and Hong Kong to investigate the association between warfarin and hazard of cancer using a new-user active-comparator cohort design. People with atrial fibrillation aged ≥ 18 years who had first received anticoagulant treatment during 01/01/2011–31/12/2019 were involved.

Results

No evidence supported the association between warfarin and hazard of overall cancer, compared with direct oral anticoagulants in both settings (England: hazard ratio [HR] = 1.03, 95% confidence interval [CI] 0.94–1.13; Hong Kong: HR = 0.89, 95% CI 0.79–1.01). A lower hazard of female breast (HR = 0.49, 95% CI 0.30–0.79), ovarian (HR = 0.07, 95% CI 0.01–0.58), and pancreatic (HR = 0.46, 95% CI 0.22–0.96) cancers and a higher hazard of kidney cancer (HR = 3.57, 95% CI 1.64–7.76) were found in Hong Kong, comparing warfarin with direct oral anticoagulants, but these were not replicated in England.

Conclusions

This study does not find a protective effect of warfarin against cancer versus direct oral anticoagulants. The risks of site-specific cancers including pancreatic, kidney, and sex-specific cancers between oral anticoagulants shown in the Hong Kong setting only may require further investigation in other independent datasets.